PT2836502T - Um novo metabolito de colesterol, 5-colesten, 3, 25-diol, dissulfato (25hcds) para terapia de distúrbios metabólicos, hiperlipidemia, diabetes, doenças do fígado gorduroso e aterosclerose - Google Patents

Um novo metabolito de colesterol, 5-colesten, 3, 25-diol, dissulfato (25hcds) para terapia de distúrbios metabólicos, hiperlipidemia, diabetes, doenças do fígado gorduroso e aterosclerose

Info

Publication number
PT2836502T
PT2836502T PT137759742T PT13775974T PT2836502T PT 2836502 T PT2836502 T PT 2836502T PT 137759742 T PT137759742 T PT 137759742T PT 13775974 T PT13775974 T PT 13775974T PT 2836502 T PT2836502 T PT 2836502T
Authority
PT
Portugal
Prior art keywords
25hcds
cholesten
3beta
disulfate
hyperlipidemia
Prior art date
Application number
PT137759742T
Other languages
English (en)
Inventor
Ren Shunlin
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Publication of PT2836502T publication Critical patent/PT2836502T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT137759742T 2012-04-12 2013-03-15 Um novo metabolito de colesterol, 5-colesten, 3, 25-diol, dissulfato (25hcds) para terapia de distúrbios metabólicos, hiperlipidemia, diabetes, doenças do fígado gorduroso e aterosclerose PT2836502T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623203P 2012-04-12 2012-04-12
US201261623414P 2012-04-12 2012-04-12

Publications (1)

Publication Number Publication Date
PT2836502T true PT2836502T (pt) 2017-10-27

Family

ID=49328028

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137759742T PT2836502T (pt) 2012-04-12 2013-03-15 Um novo metabolito de colesterol, 5-colesten, 3, 25-diol, dissulfato (25hcds) para terapia de distúrbios metabólicos, hiperlipidemia, diabetes, doenças do fígado gorduroso e aterosclerose

Country Status (21)

Country Link
US (6) US20150072962A1 (pt)
EP (2) EP3239163A1 (pt)
JP (4) JP6125610B2 (pt)
KR (1) KR102180485B1 (pt)
CN (2) CN104220450B (pt)
AU (2) AU2013246435B2 (pt)
BR (1) BR112014025081B1 (pt)
CA (1) CA2867694C (pt)
DK (1) DK2836502T3 (pt)
EA (1) EA026683B1 (pt)
ES (1) ES2641841T3 (pt)
HK (1) HK1202294A1 (pt)
HU (1) HUE035073T2 (pt)
IL (1) IL234892B (pt)
IN (1) IN2014KN02366A (pt)
MX (1) MX357046B (pt)
PL (1) PL2836502T3 (pt)
PT (1) PT2836502T (pt)
SI (1) SI2836502T1 (pt)
WO (1) WO2013154752A1 (pt)
ZA (1) ZA201406981B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
BR112014025081B1 (pt) * 2012-04-12 2020-12-08 Virginia Commonwealth University metabólito de colesterol, 5-colesten-3,25-diol, dissulfato (25hcds), seu uso, composições compreendendo o mesmo, bem como processos de produção do referido composto e da referida composição
HRP20220112T1 (hr) 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
TWI547280B (zh) * 2014-04-24 2016-09-01 長弘生物科技股份有限公司 穩定醫藥組合物
WO2016007762A1 (en) 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
KR20170066507A (ko) * 2014-10-10 2017-06-14 버지니아 커먼웰스 유니버시티 약화된 렙틴 활성 및 지질 저장 장애 중 하나 이상에 의해 야기되는 장애의 치료용 산소첨가된 콜레스테롤 술페이트
EP3237377A4 (en) * 2014-12-24 2018-08-22 Kyoto University Vitamin d3 derivatives and pharmaceutical use thereof
EA201990438A1 (ru) 2016-08-02 2019-08-30 Вирджиния Коммонвелт Юниверсити Композиции, содержащие 5-холестен-3,25-диол, 3-сульфат (25hc3s) или его фармацевтически приемлемую соль и по меньшей мере один циклический олигосахарид, и способы их применения
EP3493671A4 (en) 2016-08-02 2020-04-08 Virginia Commonwealth University USE OF OXYGENATED CHOLESTEROL INSULATES (OCS) FOR TREATING INFLAMMATIVE SKIN DISEASES AND SKIN LESIONS
JP7048576B2 (ja) * 2016-08-02 2022-04-05 デュレクト コーポレーション 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物
WO2018132676A1 (en) 2017-01-13 2018-07-19 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
KR101892577B1 (ko) 2017-04-21 2018-08-28 부산대학교 산학협력단 레블라스타틴 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 조성물
CN107286160A (zh) * 2017-06-05 2017-10-24 毛佳婧 一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法
EP3675888A4 (en) * 2017-08-31 2021-04-21 Ariel Scientific Innovations Ltd. S. SPINOSUM EXTRACT FOR FAT LIVER TREATMENT
JP2022549621A (ja) * 2019-09-30 2022-11-28 デュレクト コーポレーション アルコール性肝炎の処置
JP2023532866A (ja) * 2020-06-26 2023-08-01 デュレクト コーポレーション 自己免疫状態を処置するための酸素化コレステロールスルフェート類の使用
CN112294827B (zh) * 2020-11-12 2021-12-24 四川大学华西医院 5-胆甾烯 -3β-醇硫酸酯盐的用途
KR20230061860A (ko) 2021-10-29 2023-05-09 부산대학교 산학협력단 크산틴 유도체를 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 약학적 조성물
WO2024008614A1 (en) * 2022-07-08 2024-01-11 Société des Produits Nestlé S.A. Use of 25-hydroxycholesterol for diabetic treatment and/or prevention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372493A1 (en) * 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8044243B2 (en) 2006-02-13 2011-10-25 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2009002873A1 (en) 2007-06-22 2008-12-31 Cvi Pharmaceuticals Limited Compounds, compositions and methods for reducing lipid levels
WO2011077245A2 (en) * 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
BR112014025081B1 (pt) * 2012-04-12 2020-12-08 Virginia Commonwealth University metabólito de colesterol, 5-colesten-3,25-diol, dissulfato (25hcds), seu uso, composições compreendendo o mesmo, bem como processos de produção do referido composto e da referida composição

Also Published As

Publication number Publication date
EP2836502A1 (en) 2015-02-18
SI2836502T1 (sl) 2017-11-30
HUE035073T2 (en) 2018-05-02
JP2019089777A (ja) 2019-06-13
AU2013246435A1 (en) 2014-10-16
AU2013246435B2 (en) 2017-10-05
US20150072962A1 (en) 2015-03-12
EP2836502A4 (en) 2015-08-19
US20190135856A1 (en) 2019-05-09
AU2017268646B2 (en) 2019-07-11
US20180127457A1 (en) 2018-05-10
EP3239163A1 (en) 2017-11-01
CN104220450A (zh) 2014-12-17
EA201491859A1 (ru) 2015-02-27
US20210238219A1 (en) 2021-08-05
US20200157140A1 (en) 2020-05-21
HK1202294A1 (en) 2015-09-25
KR20150013520A (ko) 2015-02-05
JP6125610B2 (ja) 2017-05-10
MX2014012324A (es) 2015-05-11
EP2836502B1 (en) 2017-08-02
IN2014KN02366A (pt) 2015-05-01
WO2013154752A1 (en) 2013-10-17
IL234892B (en) 2019-02-28
MX357046B (es) 2018-06-22
BR112014025081B1 (pt) 2020-12-08
JP2015512937A (ja) 2015-04-30
JP2021138713A (ja) 2021-09-16
ZA201406981B (en) 2016-05-25
CA2867694A1 (en) 2013-10-17
CN106083976B (zh) 2018-02-09
CA2867694C (en) 2021-08-31
BR112014025081A2 (pt) 2018-05-08
EA026683B1 (ru) 2017-05-31
CN104220450B (zh) 2016-07-06
AU2017268646A1 (en) 2017-12-21
ES2641841T3 (es) 2017-11-14
KR102180485B1 (ko) 2020-11-18
PL2836502T3 (pl) 2018-01-31
CN106083976A (zh) 2016-11-09
US20160355544A1 (en) 2016-12-08
JP2017160213A (ja) 2017-09-14
DK2836502T3 (en) 2017-10-23

Similar Documents

Publication Publication Date Title
HK1202294A1 (en) A novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis 5--325-(25hcds)
HK1213661A1 (zh) 在多顯示屏上應用工作流的協調
EP2783252A4 (en) METHOD OF USING EYE TRACKING FOR CONCENTRATING ON AN IMAGE CONTENT ON A DISPLAY
GB2552405B (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
WO2012118769A9 (en) Immersive display experience
EP2701815A4 (en) CONTROL OF SEPARATE COMPUTER GAME ELEMENTS
EP2715539A4 (en) DISTRIBUTED CALCULATION FRAMEWORK
EP2866911A4 (en) CONVERSION OF HAPTIC EVENTS IN SCREENING EVENTS
ZA201309205B (en) Composition useful for the treatment of lipid metabolism disorders
GB201119861D0 (en) Method of operating a heterogeneous computer system
IL231635A0 (en) A selective metabolic approach to accelerated oral bioabsorption of phenylephrine and other phenolics
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
ZA201500171B (en) Method and mechanism for human computer interaction
ZA201400326B (en) Bouillon tablet process
EP2751091A4 (en) PRODUCTS FOR ANTI-INFLAMMATORY CARRIER
HK1148900A2 (en) The support frame of tablet computer
EP2742503A4 (en) APPARATUS RELATING TO PHYSICALLY DISCRETE SIGN COMPONENTS
GB2491100B (en) Operating a server computer
EP2771757A4 (en) MANAGEMENT OF A COMPUTER
GB201109913D0 (en) Lipid metabolism
AU2012902788A0 (en) Method of treating glucose metabolism disorders
GB201114920D0 (en) A computer display
AU336137S (en) Tablet computer stand
GB201205959D0 (en) Software patent application for internet pos solution
GB201117141D0 (en) Interactive display screen